1. In this randomized controlled trial, adults with mixed hyperlipidemia who received zodasiran had dose-dependent decreases in triglyceride levels compared to those who received placebo. 2. Patients who received the highest dose of zodasiran had transiently increased glycated hemoglobin levels, returning to baseline with treatment. Evidence Rating Level: 1 (Excellent) Study Rundown: Mixed hyperlipidemia is